Trulicity and Bydureon are the first once WEEKLY GLP-1 agonists

Trulicity (TRUE-lih-sih-tee, dulaglutide) and Bydureon (by-DUR-ee-on, exenatide ER) will be two new GLP-1 agonists for type 2 diabetes.

Injectable GLP-1 agonists are becoming more popular because they can lead to weight loss...and they rarely cause hypoglycemia.

Be familiar with how the GLP-1 agonists stack up.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote